KR101860459B1 - 항체 조제물 - Google Patents
항체 조제물 Download PDFInfo
- Publication number
- KR101860459B1 KR101860459B1 KR1020127030528A KR20127030528A KR101860459B1 KR 101860459 B1 KR101860459 B1 KR 101860459B1 KR 1020127030528 A KR1020127030528 A KR 1020127030528A KR 20127030528 A KR20127030528 A KR 20127030528A KR 101860459 B1 KR101860459 B1 KR 101860459B1
- Authority
- KR
- South Korea
- Prior art keywords
- igm
- antibody
- antibody preparation
- solution
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 190
- 230000000694 effects Effects 0.000 claims abstract description 58
- 210000002966 serum Anatomy 0.000 claims abstract description 49
- 230000024203 complement activation Effects 0.000 claims abstract description 43
- 238000001990 intravenous administration Methods 0.000 claims abstract description 30
- 241000282412 Homo Species 0.000 claims abstract description 12
- 238000000099 in vitro assay Methods 0.000 claims abstract description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 98
- 102000018358 immunoglobulin Human genes 0.000 claims description 98
- 239000000243 solution Substances 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 72
- 241000700605 Viruses Species 0.000 claims description 67
- 238000011282 treatment Methods 0.000 claims description 47
- 230000000295 complement effect Effects 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 230000002391 anti-complement effect Effects 0.000 claims description 21
- 108010008730 anticomplement Proteins 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 239000011541 reaction mixture Substances 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 229940072221 immunoglobulins Drugs 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 10
- 229960000380 propiolactone Drugs 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000007385 chemical modification Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 238000004040 coloring Methods 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 230000004872 arterial blood pressure Effects 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 244000309711 non-enveloped viruses Species 0.000 claims description 6
- 239000000356 contaminant Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 238000001728 nano-filtration Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000003118 sandwich ELISA Methods 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000009144 enzymatic modification Effects 0.000 claims description 2
- 230000003171 anti-complementary effect Effects 0.000 claims 1
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 92
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 46
- 102100022133 Complement C3 Human genes 0.000 description 45
- 230000002797 proteolythic effect Effects 0.000 description 36
- 238000010306 acid treatment Methods 0.000 description 25
- 238000011534 incubation Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 239000012460 protein solution Substances 0.000 description 20
- 102000006395 Globulins Human genes 0.000 description 19
- 108010044091 Globulins Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000002779 inactivation Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000003805 vibration mixing Methods 0.000 description 10
- 229920005654 Sephadex Polymers 0.000 description 9
- 239000012507 Sephadex™ Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012537 formulation buffer Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 229940078499 tricalcium phosphate Drugs 0.000 description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- 238000011891 EIA kit Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003593 chromogenic compound Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000424 optical density measurement Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001032 anti-candidal effect Effects 0.000 description 3
- 229940125717 barbiturate Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 108010035369 Cohn fraction I Proteins 0.000 description 2
- 108010044316 Cohn fraction III Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000012418 validation experiment Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- XHTORJWGZKCDGL-GRGSLBFTSA-N (2s)-1-[(2r,3r)-2-amino-3-methylpentanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 XHTORJWGZKCDGL-GRGSLBFTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710172562 Cobra venom factor Proteins 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010075079 isoleucyl-prolyl-arginine-4-nitroanilide Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- MHQHHBYRYFICDV-UHFFFAOYSA-M sodium;pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1CC(=O)[N-]C(=O)N1 MHQHHBYRYFICDV-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1006753.6A GB201006753D0 (en) | 2010-04-22 | 2010-04-22 | Process for preparing an immunolobulin composition |
| GB1006753.6 | 2010-04-22 | ||
| PCT/EP2011/056487 WO2011131787A2 (en) | 2010-04-22 | 2011-04-21 | Antibody preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130060199A KR20130060199A (ko) | 2013-06-07 |
| KR101860459B1 true KR101860459B1 (ko) | 2018-05-23 |
Family
ID=42270688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127030528A Active KR101860459B1 (ko) | 2010-04-22 | 2011-04-21 | 항체 조제물 |
| KR1020127030527A Active KR101872747B1 (ko) | 2010-04-22 | 2011-04-21 | 면역글로불린 조성물의 제조 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127030527A Active KR101872747B1 (ko) | 2010-04-22 | 2011-04-21 | 면역글로불린 조성물의 제조 방법 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9243056B2 (enExample) |
| EP (2) | EP2560691B1 (enExample) |
| JP (4) | JP6283517B2 (enExample) |
| KR (2) | KR101860459B1 (enExample) |
| CN (3) | CN107080842A (enExample) |
| AU (2) | AU2011244241B2 (enExample) |
| CA (2) | CA2796263C (enExample) |
| CO (2) | CO6640239A2 (enExample) |
| ES (2) | ES2553385T3 (enExample) |
| GB (1) | GB201006753D0 (enExample) |
| HU (2) | HUE028581T2 (enExample) |
| IL (2) | IL222373A (enExample) |
| MX (2) | MX337060B (enExample) |
| PL (2) | PL2560682T5 (enExample) |
| RU (4) | RU2612899C2 (enExample) |
| SG (2) | SG184844A1 (enExample) |
| WO (2) | WO2011131786A2 (enExample) |
| ZA (2) | ZA201208540B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| FR2959821B1 (fr) * | 2010-05-05 | 2012-07-06 | Lab Francais Du Fractionnement | Procede de mesure de l'activation du complement par des igg |
| FR2974301B1 (fr) | 2011-04-20 | 2013-08-23 | Lab Francais Du Fractionnement | Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes |
| FR2977893B1 (fr) * | 2011-07-11 | 2015-02-20 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre d'immunoglobulines polyvalentes |
| EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
| EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
| WO2013132052A1 (en) * | 2012-03-09 | 2013-09-12 | Csl Behring Ag | Compositions comprising secretory - like immunoglobulins |
| KR20150115639A (ko) * | 2014-04-04 | 2015-10-14 | 전숙영 | 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제 |
| WO2016011054A2 (en) * | 2014-07-15 | 2016-01-21 | The Regents Of The University Of California | Novel treatment for polycystic kidney disease |
| WO2017027861A1 (en) | 2015-08-13 | 2017-02-16 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
| WO2017157850A1 (en) | 2016-03-14 | 2017-09-21 | Biotest Ag | Treatment of severe community acquired pneumonia |
| EP3275897A1 (en) | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
| RU2660584C1 (ru) * | 2017-06-06 | 2018-07-06 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ определения FC-функции препаратов иммуноглобулина человека |
| KR102551444B1 (ko) * | 2017-11-29 | 2023-07-06 | 에프. 호프만-라 로슈 아게 | 표적 간섭이 억제된 항-약물 항체 분석 |
| EP3747903A1 (en) | 2019-06-07 | 2020-12-09 | Biotest AG | Method and kit for testing potency of immunoglobulin compositions |
| AU2021251423A1 (en) * | 2020-04-10 | 2022-10-27 | Vanudis GmbH | Natural antibodies in prophylaxis and therapy |
| CA3180876A1 (en) * | 2020-06-03 | 2021-12-09 | Grifols Worldwide Operations Limited | Hyperimmune igg and/or igm compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor |
| AR122931A1 (es) * | 2020-07-10 | 2022-10-19 | Grifols Worldwide Operations Ltd | Procedimiento para obtener una composición que comprende inmunoglobulina m derivada de plasma humano |
| CN111944043B (zh) * | 2020-09-01 | 2023-05-09 | 华兰生物工程重庆有限公司 | 一种从血浆废弃物中提取IgM的方法 |
| WO2022106546A1 (en) | 2020-11-19 | 2022-05-27 | Biotest Ag | Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19 |
| IL310068A (en) | 2021-07-29 | 2024-03-01 | Csl Behring Ag | Immunoglobulin G purification method and its uses |
| WO2024200757A1 (en) | 2023-03-29 | 2024-10-03 | Csl Behring Ag | Methods of identifying immunoglobulin associated with adverse reactions |
| WO2025008781A1 (en) | 2023-07-04 | 2025-01-09 | Csl Behring Ag | Method of purification |
| WO2025229607A1 (en) | 2024-05-03 | 2025-11-06 | Csl Behring Ag | Systems and methods for solid-liquid separation |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US136556A (en) | 1873-03-04 | Improvements in button-fastenings | ||
| DE2901822A1 (de) | 1979-01-18 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt |
| US4371520A (en) * | 1981-10-28 | 1983-02-01 | The Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
| DE3310150A1 (de) * | 1983-03-21 | 1984-09-27 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation |
| IL90281A (en) | 1988-06-06 | 1994-10-07 | Miles Inc | Preparations containing MGI antibodies |
| DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
| US4939176A (en) | 1988-12-20 | 1990-07-03 | Miles Inc. | Viral inactivation process |
| DE3927112C1 (enExample) | 1989-08-17 | 1990-10-25 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| DE3927111C3 (de) * | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| US5367054A (en) * | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| CA2225470C (en) | 1995-07-14 | 2010-06-29 | Croix-Rouge De Belgique | Method and apparatus for inactivating contaminants in blood products |
| ES2170788T3 (es) | 1995-09-22 | 2002-08-16 | Zlb Bioplasma Ag | Procedimiento para la obtencion de inmunoglobulinas a partir de fracciones que resultan de plasma sanguineo humano. |
| EP0835880A1 (de) * | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
| JP3987599B2 (ja) * | 1996-12-05 | 2007-10-10 | 日本製薬株式会社 | 筋ジストロフィー治療剤 |
| JPH10167894A (ja) * | 1996-12-11 | 1998-06-23 | Mitsubishi Gas Chem Co Inc | ビスマス置換希土類鉄ガーネット単結晶膜の製造法 |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
| PL196770B1 (pl) | 1998-06-09 | 2008-01-31 | Statens Seruminstitut | Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie |
| RU2178309C2 (ru) * | 2000-01-12 | 2002-01-20 | Российский научно-исследовательский институт геронтологии | Антитимоцитарный глобулин для внутривенного введения и способ его получения |
| RU2192279C2 (ru) * | 2000-09-07 | 2002-11-10 | Нижегородское государственное предприятие по производству бактерийных препаратов | Способ получения иммуноглобулинового препарата |
| CA2428332C (en) | 2000-11-13 | 2010-05-25 | Bayer Aktiengesellschaft | Method of inactivating microorganisms in a fluid using ultraviolet radiation |
| FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
| WO2003037504A1 (en) | 2001-11-02 | 2003-05-08 | Japan Techno Co., Ltd. | Vibratory stirrer for sterilization and sterilizer and sterilization method employing vibratory stirrer |
| RU2255766C2 (ru) * | 2003-03-05 | 2005-07-10 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" | Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата |
| US8980646B2 (en) | 2003-03-26 | 2015-03-17 | Sudhir Paul | Proteolytic and covalent antibodies |
| KR101221862B1 (ko) | 2003-10-27 | 2013-01-14 | 와이어쓰 엘엘씨 | 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거 |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| KR20070009995A (ko) | 2004-01-30 | 2007-01-19 | 수오멘 푸나이넨 리스티 베리팔베루 | 바이러스 안전성 면역글로불린을 제조하는 방법 |
| PT1718675E (pt) | 2004-02-27 | 2013-05-21 | Octapharma Ag | Método de proporcionar uma preparação purificada de anticorpos livre de vírus |
| DE602005021694D1 (de) | 2004-12-10 | 2010-07-15 | Novimmune Sa | Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung |
| WO2006064373A2 (en) | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
| KR101157174B1 (ko) | 2005-11-24 | 2012-06-20 | 삼성전자주식회사 | 세포 또는 바이러스의 신속한 파괴 방법 및 장치 |
| DE102005062634A1 (de) | 2005-12-23 | 2007-06-28 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung |
| FR2899111B1 (fr) | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. |
| FR2899112B1 (fr) | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament. |
| US8354076B2 (en) | 2006-10-02 | 2013-01-15 | Palo Alto Research Center Incorporated | Fluid stirring mechanism |
| EP1950225A1 (de) | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
| EP2291196A4 (en) | 2008-05-12 | 2012-05-30 | Strox Biopharmaceuticals Llc | FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS |
| RU2457861C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
| RU2457863C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| NZ591514A (en) | 2011-03-03 | 2013-11-29 | Kode Biotech Ltd | Assay method |
-
2010
- 2010-04-22 GB GBGB1006753.6A patent/GB201006753D0/en not_active Ceased
-
2011
- 2011-04-21 JP JP2013511592A patent/JP6283517B2/ja active Active
- 2011-04-21 SG SG2012076063A patent/SG184844A1/en unknown
- 2011-04-21 MX MX2012012262A patent/MX337060B/es active IP Right Grant
- 2011-04-21 RU RU2012149743A patent/RU2612899C2/ru active
- 2011-04-21 HU HUE11715928A patent/HUE028581T2/en unknown
- 2011-04-21 RU RU2016140455A patent/RU2765738C2/ru active
- 2011-04-21 KR KR1020127030528A patent/KR101860459B1/ko active Active
- 2011-04-21 ES ES11715928.5T patent/ES2553385T3/es active Active
- 2011-04-21 RU RU2012149741A patent/RU2617532C2/ru active
- 2011-04-21 EP EP11715928.5A patent/EP2560691B1/en active Active
- 2011-04-21 KR KR1020127030527A patent/KR101872747B1/ko active Active
- 2011-04-21 WO PCT/EP2011/056486 patent/WO2011131786A2/en not_active Ceased
- 2011-04-21 RU RU2017111820A patent/RU2749732C2/ru active
- 2011-04-21 PL PL11715567.1T patent/PL2560682T5/pl unknown
- 2011-04-21 MX MX2012012263A patent/MX338195B/es active IP Right Grant
- 2011-04-21 AU AU2011244241A patent/AU2011244241B2/en active Active
- 2011-04-21 CN CN201611045494.0A patent/CN107080842A/zh active Pending
- 2011-04-21 SG SG2012076055A patent/SG184843A1/en unknown
- 2011-04-21 WO PCT/EP2011/056487 patent/WO2011131787A2/en not_active Ceased
- 2011-04-21 CN CN201180029338.4A patent/CN102939111B/zh active Active
- 2011-04-21 PL PL11715928T patent/PL2560691T3/pl unknown
- 2011-04-21 AU AU2011244240A patent/AU2011244240B2/en active Active
- 2011-04-21 ES ES11715567T patent/ES2551605T5/es active Active
- 2011-04-21 CA CA2796263A patent/CA2796263C/en active Active
- 2011-04-21 HU HUE11715567A patent/HUE025853T2/en unknown
- 2011-04-21 EP EP11715567.1A patent/EP2560682B2/en active Active
- 2011-04-21 CA CA2796409A patent/CA2796409A1/en not_active Abandoned
- 2011-04-21 JP JP2013511591A patent/JP6118248B2/ja active Active
- 2011-04-21 CN CN201180029337.XA patent/CN102939107B/zh active Active
-
2012
- 2012-10-11 IL IL222373A patent/IL222373A/en active IP Right Grant
- 2012-10-11 IL IL222374A patent/IL222374A/en active IP Right Grant
- 2012-10-19 US US13/655,649 patent/US9243056B2/en active Active
- 2012-10-19 US US13/655,686 patent/US8900806B2/en active Active
- 2012-11-13 ZA ZA2012/08540A patent/ZA201208540B/en unknown
- 2012-11-13 ZA ZA2012/08541A patent/ZA201208541B/en unknown
- 2012-11-22 CO CO12211856A patent/CO6640239A2/es unknown
- 2012-11-22 CO CO12211854A patent/CO6640238A2/es not_active Application Discontinuation
-
2014
- 2014-10-31 US US14/529,400 patent/US9518110B2/en active Active
-
2016
- 2016-06-01 JP JP2016110121A patent/JP6612182B2/ja active Active
- 2016-06-15 JP JP2016118887A patent/JP6612186B2/ja active Active
- 2016-11-10 US US15/348,121 patent/US10059759B2/en active Active
-
2018
- 2018-07-09 US US16/029,781 patent/US10954290B2/en active Active
-
2021
- 2021-02-05 US US17/168,848 patent/US11780909B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101860459B1 (ko) | 항체 조제물 | |
| HK1180601B (en) | Antibody preparations | |
| HK1177600B (en) | Process for preparing an immunoglobulin composition | |
| BR112012026937B1 (pt) | Preparação de anticorpo apropriada para administração intravenosa em humanos, e, uso da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20121121 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160408 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170714 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180226 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180516 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20180516 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20210415 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220329 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230329 Start annual number: 6 End annual number: 6 |